Unknown

Dataset Information

0

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts.


ABSTRACT: Acute myeloid leukemia (AML) in children remains deadly, despite the use of maximally intensive therapy. Because leukemia stem cells (LSCs) significantly contribute to chemoresistance and relapse, therapies that specifically target the LSCs are likely to be more beneficial in improving outcome. LSCs are known to have high telomerase activity and telomerase activity is negatively correlated with survival in pediatric AML. We evaluated the preclinical efficacy of imetelstat, an oligonucleotide inhibitor of telomerase activity in patient-derived xenograft (PDX) lines of pediatric AML. Imetelstat treatment significantly increased apoptosis/death of the LSC population in a dose-dependent manner in six pediatric AML PDX lines ex vivo, while it had limited activity on the stem cell population in normal bone marrow specimens. These results were validated in vivo in two distinct PDX models wherein imetelstat as single agent or in combination with chemotherapy greatly reduced the LSC percentage and prolonged median survival. Imetelstat combination with DNA hypomethylating agent azacitidine was also beneficial in extending survival. Secondary transplantation experiments showed delayed engraftment and improved survival of mice receiving imetelstat-treated cells, confirming the diminished LSC population. Thus, our data suggest that imetelstat represents an effective therapeutic strategy for pediatric AML.

SUBMITTER: Barwe SP 

PROVIDER: S-EPMC8999576 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts.

Barwe Sonali P SP   Huang Fei F   Kolb Edward Anders EA   Gopalakrishnapillai Anilkumar A  

Journal of clinical medicine 20220330 7


Acute myeloid leukemia (AML) in children remains deadly, despite the use of maximally intensive therapy. Because leukemia stem cells (LSCs) significantly contribute to chemoresistance and relapse, therapies that specifically target the LSCs are likely to be more beneficial in improving outcome. LSCs are known to have high telomerase activity and telomerase activity is negatively correlated with survival in pediatric AML. We evaluated the preclinical efficacy of imetelstat, an oligonucleotide inh  ...[more]

Similar Datasets

2023-07-14 | GSE176523 | GEO
| PRJNA736609 | ENA
| S-EPMC8670248 | biostudies-literature
2015-10-24 | GSE74299 | GEO
2015-10-24 | E-GEOD-74299 | biostudies-arrayexpress
2023-07-14 | GSE176524 | GEO
2019-03-15 | GSE117599 | GEO
| PRJNA736604 | ENA
2014-05-20 | GSE57795 | GEO
2014-05-20 | E-GEOD-57795 | biostudies-arrayexpress